• 1
    Gurney JG, Young JL, Roffers SD, Smith MA, Bunin GR. Soft Tissue Sarcomas. SEER Pediatric Monograph. Bethesda, Md: National Cancer Institute; 2005.
  • 2
    Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute; 1999.
  • 3
    Stout AP. Rhabdomyosarcoma of the skeletal muscles. Ann Surg. 1946; 123: 447-472.
  • 4
    Grufferman S, Wang HH, DeLong ER, Kimm SY, Delzell ES, Falletta JM. Environmental factors in the etiology of rhabdomyosarcoma in childhood. J Natl Cancer Inst. 1982; 68: 107-113.
  • 5
    Grufferman S, Gula MJ, Olshan AF, et al. In utero x-ray exposure and risk of childhood rhabdomyosarcoma [abstract]. Paediatr Perinat Epidemiol. 1991; 5: A6.
  • 6
    Hartley AL, Birch JM, McKinney PA, et al. The Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): case control study of children with bone and soft tissue sarcomas. Br J Cancer. 1988; 58: 838-842.
  • 7
    Ghali MH, Yoo KY, Flannery JT, Dubrow R. Association between childhood rhabdomyosarcoma and maternal history of stillbirths. Int J Cancer. 1992; 50: 365-368.
  • 8
    Grufferman S, Schwartz AG, Ruymann FB, Maurer HM. Parents' use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control. 1993; 4: 217-224.
  • 9
    Yang P, Grufferman S, Khoury MJ, et al. Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol. 1995; 12: 467-474.
  • 10
    Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999; 4: 34-44.
  • 11
    Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 240: 1233-1238.
  • 12
    Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV. J Pediatr. 2004; 133: 666-668.
  • 13
    Smith AC, Squire JA, Thorner P, et al. Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. Pediatr Dev Pathol. 2001; 4: 550-558.
  • 14
    Hennekam RC. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet. 2003; 117C: 42-48.
  • 15
    Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003; 63: 6643-66450.
  • 16
    Moutou C, Le Bihan C, Chompret A, et al. Genetic transmission of susceptibility to cancer in families of children with soft tissue sarcomas. Cancer. 1996; 78: 1483-1491.
  • 17
    Maurer HM. Rhabdomyosarcoma in childhood and adolescence. Curr Probl Cancer. 1978; 2: 1-36.
  • 18
    Ruymann FB, Maddux HR, Ragab A, et al. Congenital anomalies associated with rhabdomyosarcoma: an autopsy study of 115 cases. A report from the Intergroup Rhabdomyosarcoma Study Committee (representing the Children's Cancer Study Group, the Pediatric Oncology Group, the United Kingdom Children's Cancer Study Group, and the Pediatric Intergroup Statistical Center). Med Pediatr Oncol. 1988; 16: 33-39.
  • 19
    Centers for Disease Control and Prevention (CDC). Birth Defects: Frequently Asked Questions. Atlanta, Ga: Centers for Disease Control and Prevention; 2006.
  • 20
    Pappo A, ed. Pediatric Bone and Soft Tissue Sarcomas. Heidelberg, Germany: Springer; 2006.
  • 21
    Linabery AM, Ross JA. Trends in childhood cancer incidence in the US. (1992-2004). Cancer. 2008; 112: 416-432.
  • 22
    Surveillance, Epidemiology, and End Results (SEER) Program. Limited-use Data (1975-2005). Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission. Available at: Accessed on June 5, 2009.
  • 23
    Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer. 1995; 76: 2343-2350.
  • 24
    Fritz AG, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 25
    Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005; 103: 1457-1467.
  • 26
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat software, version 6.3.6. Bethesda, Md: Surveillance Research Program, National Cancer Institute. Available at: Accessed on June 5, 2009.
  • 27
    National Cancer Institute. Joinpoint Regression Program, Version 3.0. Bethesda, Md: Statistical Research and Applications Branch, National Cancer Institute, April 2005. Available at: Accessed on June 5, 2009.
  • 28
    Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961; 6: 101-121.
  • 29
    Brown CC. The statistical comparison of relative survival rates. Biometrics. 1983; 39: 941-948.
  • 30
    PercyC, Van HoltenV, MuirC, eds. International Classification of Disease for Oncology. 2nd ed. Geneva, Switzerland: World Health Organization; 1992.
  • 31
    World Health Organization. International Classification of Diseases for Oncology (ICD-O). 1st ed. Geneva, Switzerland: World Health Organization; 1976.
  • 32
    Newton WAJr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification—an Intergroup Rhabdomyosarcoma Study. Cancer. 1995; 76: 1073-1085.
  • 33
    Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol. 1998; 1: 550-561.
  • 34
    Triche TJ, Hicks J, Sorensen PHB. Diagnostic pathologies of pediatric malignancies. In: PizzoPA, PoplackDG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2006.
  • 35
    Edwards RH, Chatten J, Xiong QB, Barr FG. Detection of gene fusions in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction assay of archival samples. Diagn Mol Pathol. 1998; 6: 91-97.
  • 36
    Hogler W, Blimkie CJ, Cowell CT, et al. Sex-specific developmental changes in muscle size and bone geometry at the femoral shaft. Bone. 2008; 42: 982-989.
  • 37
    Lae M, Ahn EH, Mercado GE, et al. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol. 2007; 212: 143-151.
  • 38
    Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006; 66: 6936-6946.
  • 39
    Feinberg AP. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res. 1999; 59: 743s-1746s.
  • 40
    Barr FG, Meyer WH. Rhabdomyosarcoma: An Overview of Biology, Clinical Features and the Current Children's Oncology Group Studies. ASCO Educational Book. Alexandria, Va: American Society for Clinical Oncology; 2008.
  • 41
    Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001; 20: 5736-5746.
  • 42
    Papaefthymiou MA, Giaginis CT, Theocharis SE. DNA repair alterations in common pediatric malignancies. Med Sci Monit. 2008; 14: RA8-RA15.
  • 43
    Mosor M, Ziolkowska I, Januszkiewicz-Lewandowska D, Nowak J. Polymorphisms and haplotypes of the NBS1 gene in childhood acute leukaemia. Eur J Cancer. 2008; 44: 2226-2232.
  • 44
    McNeil DE, Cote TR, Clegg L, Mauer A. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol. 2002; 39: 554-557; discussion 552-553.